SC
NKTR icon

SummitTX Capital’s Nektar Therapeutics NKTR Stock Holding History

SummitTX Capital’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.88M Buy
112,934
+70,310
+165% +$5.14M 0.2% 127
2026
Q1 		$3.07M Buy
42,624
+11,271
+36% +$642K 0.1% 232
2025
Q4 		$1.33M Buy
31,353
+24,555
+361% +$1.37M 0.04% 368
2025
Q3 		$387K Sell
6,798
-5,628
-45% -$186K 0.02% 577
2025
Q2 		$321K Buy
+12,426
New +$140K 0.01% 599

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SummitTX Capital's NKTR Position: Q2 2026 in Review

SummitTX Capital increased its Nektar Therapeutics (NKTR) stake by 165% in Q2 2026, buying an estimated $5.14M and bringing the position to 112,934 shares worth $7.88M. The position accounts for 0.2% of the portfolio, ranked #127.

SummitTX Capital first reported a position in NKTR in Q2 2025 and has held it in 5 quarters since. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • SummitTX Capital held 112,934 shares of Nektar Therapeutics worth $7.88M as of Q2 2026.
  • SummitTX Capital bought 70,310 Nektar Therapeutics shares in Q2 2026, an estimated $5.14M.
  • Nektar Therapeutics made up 0.2% of SummitTX Capital's portfolio in Q2 2026, its #127 holding.
  • SummitTX Capital first reported a position in Nektar Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.